Physician profile
Christopher Mueller
NPI 1295977718
$9,693.18
in general payments reported to CMS, 2019-2025
9 companies · $53.49 in 2025
The $53.49 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,302 · 2020: $2,965 · 2021: $150 · 2022: $24.65 · 2023: $22.95 · 2024: $174 · 2025: $53.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $4,751.04 | 2019 | |
| Akcea Therapeutics, INC. | $4,666.63 | 2019-2021 | |
| Pfizer INC. | $96.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $64.02 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $31.96 | 2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.27 | 2024 | Lifevest |
| Edwards Lifesciences Corporation | $22.95 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Amgen INC. | $13.70 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.